Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics
(PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination
with febuxostat (xanthine oxidase inhibitor) in patients with gout.
[1
]
Metroplex Clinical Research Center, Dallas, TX, Ardea Biosciences and Translational
Sciences Department, Clinical Department, Regulatory Department and Biology Department,
Ardea Biosciences, San Diego, CA, USA. rfleischmann@mcrcdallas.com.
[2
]
Metroplex Clinical Research Center, Dallas, TX, Ardea Biosciences and Translational
Sciences Department, Clinical Department, Regulatory Department and Biology Department,
Ardea Biosciences, San Diego, CA, USA.